1. A control circuit for a switch mode DC-DC converter comprising an arrangement of LGATE, UGATE and PHASE node condition threshold detectors, said LGATE condition threshold detector being operative to monitor the gate (LGATE) of a lower FET (LFET), said UGATE condition threshold detector being operative to monitor the gate (UGATE) of an upper FET (UFET), and said PHASE node condition threshold detector being operative to monitor a phase node voltage at a PHASE node or common node between said UFET and said LFET, voltage outputs of said threshold detectors being processed in accordance with a switching control operator to ensure that each of said UFET and said LFET is completely turned off before the other FET begins conduction, thereby maintaining a dead time that exhibits no shoot-through current and is independent of type of switching FET, and wherein said switching control operator is operative to trigger turn-on of said UFET, which causes the phase node voltage to increase from a first voltage level to a second voltage level higher than said first voltage level, in response to turn-off of said LFET, and in response to said phase node voltage at said PHASE node having reached a prescribed negative polarity voltage threshold following a predetermined blanking delay subsequent to said turn-off of said LFET.
2. The control circuit according to claim 1, wherein said switching control operator is operatives, in response to said PHASE node not having reached said prescribed negative polarity voltage following said predetermined blanking delay subsequent to turn-off of said LFET, to monitor whether said phase node voltage has increased from said first voltage level to a prescribed positive polarity voltage threshold and, in response to said phase node voltage having increased from said first voltage level to said prescribed positive polarity voltage threshold, said switching control operator is operative to trigger turn-on of said UFET, and thereby causing said phase node voltage to increase to said second voltage level.
3. The control circuit according to claim 2, wherein said switching control operator is operative, in response to an elapse of a prescribed time-out without either of said prescribed positive and negative polarity voltage thresholds having been reached at said phase node following said blanking delay, to trigger turn-on of said LFET, causing said phase node voltage to increase from said first voltage level to said second voltage level.
4. The control circuit according to claim 1, wherein said switching control operator is operative, in response to turn-off of said UFET, and in response to a UGATE voltage at said UGATE dropping to a voltage level that is a prescribed value above said phase node voltage, to trigger a prescribed time out and then turn on said LFET in response to expiration of said prescribed time out.
5. The control circuit according to claim 1, wherein said switching control operator is operative, in response to turn-off of said UFET, and in response to said phase node voltage reaching a predetermined threshold voltage, to turn on said LFET.
6. A method for controlling a switch mode DC-DC converter comprising an upper FET (UFET), having an upper gate (UGATE), and a lowar FET (LFET) having a lower gate (LGATE), said UFET and said LFET being coupled between power supply voltage rails, and having a common node or PHASE node therebetween, said method comprising the steps of:
(a) monitoring an LGATE voltage, a UGATE voltage and a phase node voltage; and
(b) in response to turn-off of said LFET, and in response to said phase node voltage at said PHASE node having reached a prescribed negative polarity voltage threshold following a predetermined blanking delay subsequent to said turn-off of said LFET, triggering turn-on of said UFET, thereby causing said phase node voltage to increase from a first voltage level to a second voltage level higher than said first voltage level.
7. The method according to claim 6, wherein step (b) further comprises, in response to said PHASE node not having reached said prescribed negative polarity voltage following said predetermined blanking delay subsequent to turn-off of said LFET, monitoring whether said phase node voltage has increased from said first voltage level to a prescribed positive polarity voltage threshold and, in response to said phase node voltage having increased from said first voltage level to said prescribed positive polarity voltage threshold, triggering turn-on of said UFET, thereby causing said phase node voltage to increase to said second voltage level.
8. The method circuit according to claim 7, wherein step (b) further comprises, in response to an elapse of a prescribed time-out without either of said prescribed positive and negative polarity voltage thresholds having been reached at said phase node following said blanking delay, triggering turn-on of said UFET, thereby causing said phase node voltage to increase from said first voltage level to said second voltage level.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A nutraceutical composition comprising extracts of at least three or four herbs, wherein the first herb, which is optional, is Hedysarum polybotrys Hand.-Mazz. or Astragalus membranceus Bge., the second herb is Atractylodes macrocephala kodiz., the third herb is Ledebouriella seseloides (hoffm.) Wolff, and the fourth herb is an anti-allergy herb.
2. The nutraceutical composition of claim 1, wherein the fourth herb is Centipeda minimal (L.) A. Br Et Aschers.
3. The nutraceutical composition of claim 2, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
4. The nutraceutical composition of claim 2, wherein the nutraceutical composition contains extracts of only four herbs, i.e., the first, second, third, and fourth herbs; or extracts of only three herbs, i.e., the second, third, and fourth herbs
5. The nutraceutical composition of claim 4, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
6. The nutraceutical composition of claim 1, wherein the fourth herb is Magnolia biondii Pamp.
7. The nutraceutical composition of claim 6, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
8. The nutraceutical composition of claim 6, wherein the nutraceutical composition contains extracts of only four herbs, i.e., the first, second, third, and fourth herbs; or extracts of only three herbs, i.e., the second, third, and fourth herbs.
9. The nutraceutical composition of claim 8, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
10. The nutraceutical composition of claim 1, wherein the nutraceutical composition contains extracts of only four herbs, i.e., the first, second, third, and fourth herbs; or extracts of only three herbs, i.e., the second, third, and fourth herbs.
11. The nutraceutical composition of claim 10, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
12. A method of treating a disorder related to excessive secretion of histamine, comprising administering to a subject in need thereof extracts of at least three or four herbs, wherein the first herb, which is optional, is Hedysarum polybotrys Hand.-Mazz. or Astragalus membranceus Bge., the second herb is Atractylodes macrocephala kodiz., and the third herb is Ledebouriella seseloides (hoffm.) Wolff, and the fourth herb is an anti-allergy herb.
13. The method of claim 12, wherein the fourth herb is Centipeda minimal (L.) A. Br. Et Aschers or Magnolia biondii Pamp.
14. The method of claim 13, wherein the disorder is allergic rhinitis, asthma, or eczyma.
15. The method of claim 14, wherein the disorder is allergic rhinitis.
16. The method of claim 13, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
17. The method of claim 16, wherein the disorder is allergic rhinitis, asthma, or eczyma.
18. The method of claim 17, wherein the disorder is allergic rhinitis.
19. The method of claim 13, wherein the method includes administering extracts of only four herbs, i.e., the first, second, third, and fourth herbs; or extracts of only three herbs, i.e., the second, third, and fourth herbs.
20. The method of claim 19, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
21. The method of claim 20, wherein the disorder is allergic rhinitis, asthma, or eczyma.
22. The method of claim 21, wherein the disorder is allergic rhinitis.
23. The method of claim 12, wherein the disorder is allergic rhinitis, asthma, or eczyma.
24. The method of claim 23, wherein the disorder is allergic rhinitis.
25. The method of claim 12, wherein the method includes administering extracts of only four herbs, i.e., the first, second, third, and fourth herbs; or extracts of only three herbs, i.e., the second, third, and fourth herbs.
26. The method of claim 25, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
27. A method of treating a disorder related to excessive secretion of interleukin-4, comprising administering to a subject in need thereof extracts of at least three or four herbs, wherein the first herb, which is optional, is Hedysarum polybotrys Hand.-Mazz. or Astragalus membranceus Bge., the second herb is Atractylodes macrocephala kodiz., and the third herb is Ledebouriella seseloides (hoffm.) Wolff, and the fourth herb is an anti-allergy herb.
28. The method of claim 27, wherein the fourth herb is Centipeda minimal (L.) A. Br. Et Aschers or Magnolia biondii Pamp.
29. The method of claim 28, wherein the disorder is allergic rhinitis, asthma, or eczyma.
30. The method of claim 29, wherein the disorder is allergic rhinitis.
31. The method of claim 28, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
32. The method of claim 31, wherein the disorder is allergic rhinitis, asthma, or eczyma.
33. The method of claim 32, wherein the disorder is allergic rhinitis.
34. The method of claim 28, wherein the method includes administering extracts of only four herbs, i.e., the first, second, third, and fourth herbs; or extracts of only three herbs, i.e., the second, third, and fourth herbs.
35. The method of claim 34, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).
36. The method of claim 35, wherein the disorder is allergic rhinitis, asthma, or eczyma.
37. The method of claim 36, wherein the disorder is allergic rhinitis.
38. The method of claim 27, wherein the disorder is allergic rhinitis, asthma, or eczyma.
39. The method of claim 38, wherein the disorder is allergic rhinitis.
40. The method of claim 27, wherein the method includes administering extracts of only four herbs, i.e., the first, second, third, and fourth herbs; or extracts of only three herbs, i.e., the second, third, and fourth herbs.
41. The method of claim 40, wherein the weight ratio of the first, second, third, and fourth herbs is (0-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5).